Jazz Pharma director plans sale of 3,507 shares

Jazz Pharmaceuticals plc (JAZZ) is the issuer for which Norbert G. Riedel, identified as a director, has filed a notice of proposed sale of common stock under Rule 144.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) is the issuer for which Norbert G. Riedel, identified as a director, has filed a notice of proposed sale of common stock under Rule 144. The notice covers 3,507 shares of common stock, to be sold through E*TRADE Financial Corporation on or after August 31, 2026, with an indicated aggregate market value of $857,602.00. The shares derive from restricted stock vesting dated August 28, 2026 and are described as acquired from the issuer as compensation.

Key Figures

Shares to be sold: 3,507 shares of common stock Aggregate market value: $857,602.00 CUSIP: 64914577 +2 more

5 metrics

Shares to be sold 3,507 shares of common stock Proposed sale under Rule 144

Aggregate market value $857,602.00 Value of 3,507 common shares proposed to be sold

CUSIP 64914577 Identifier for Jazz Pharmaceuticals plc common stock listed in the notice

Proposed sale date 08/31/2026 Date listed for proposed sale of the 3,507 shares

Acquisition (vesting) date 08/28/2026 Restricted stock vesting date for the shares to be sold

Key Terms

Rule 144, restricted stock vesting, power of attorney

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"COMMON | 08/28/2026 | RESTRICTED STOCK VESTING | ISSUER"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

power of attorney regulatory

"Signature | /s/Paz Dizon by power of attorney for Norbert G. Riedel"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for JAZZ?

It discloses that director Norbert G. Riedel has filed a notice of intent to sell 3,507 shares of Jazz Pharmaceuticals plc common stock under Rule 144, with an indicated aggregate market value of $857,602.00, through E*TRADE Financial Corporation.

How many JAZZ shares are covered by this Form 144 notice?

The notice covers 3,507 shares of Jazz Pharmaceuticals plc common stock proposed to be sold under Rule 144.

What is the aggregate market value of the JAZZ shares in this Form 144?

The filing lists an aggregate market value of $857,602.00 for the 3,507 shares of Jazz Pharmaceuticals plc common stock covered by the notice.

When are the JAZZ shares expected to be sold under this Form 144?

The filing indicates a proposed sale date of August 31, 2026 for the 3,507 shares of Jazz Pharmaceuticals plc common stock.

How were the JAZZ shares in this Form 144 acquired?

The shares are described as restricted stock vesting on August 28, 2026 and are noted as acquired from the issuer, Jazz Pharmaceuticals plc, as compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:24 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:22 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001161662
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jazz Pharmaceuticals plc
SEC File Number	001-33500
Address of Issuer	FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN IRELAND D04 E5W7
Phone	353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	RIEDEL NORBERT G
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3507	857602.00	64914577	08/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/28/2026	RESTRICTED STOCK VESTING	ISSUER			3507	08/28/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Paz Dizon by power of attorney for Norbert G. Riedel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)